文章：

免疫疗法如何重塑转移性或局部晚期肌层浸润性尿路上皮膀胱癌的治疗模式

How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma

原文发布日期：5 May 2024

DOI: 10.3390/cancers16091780

类型: Article

开放获取: 是

英文摘要：

In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody–drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as neoadjuvants, adjuvants, or first- or second-line treatments have produced conflicting results. However, first-line therapeutic strategies have been redefined by the recent publication of results from two clinical trials: CheckMate-901, which demonstrated the superiority of combined treatment with nivolumab and chemotherapy in extending overall survival, and EV-302, which demonstrated that combined treatment with pembrolizumab and enfortumab vedotin reduced the risk of death by 53%. In this review, we discuss the role of ICIs, alone or in combination, in bladder cancer management in the metastatic and adjuvant settings in 2024, considering the latest published trials. The potential role of ICIs as neoadjuvants is also discussed.

摘要翻译： 

过去十年间，转移性膀胱癌的治疗方案显著扩展，包括免疫检查点抑制剂（ICIs）、如enfortumab vedotin的抗体偶联药物以及抗成纤维细胞生长因子受体药物的研发。评估ICIs作为新辅助、辅助或一线/二线治疗的临床试验结果存在矛盾。然而，近期公布的两项临床试验结果重新定义了一线治疗策略：CheckMate-901研究证实纳武利尤单抗联合化疗在延长总生存期方面具有优势，EV-302研究则表明帕博利珠单抗联合enfortumab vedotin治疗可将死亡风险降低53%。本综述结合最新发表的临床试验，探讨2024年ICIs单药或联合用药在转移性和辅助性膀胱癌治疗中的作用，并讨论ICIs作为新辅助治疗的潜在价值。

原文链接：

How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma